Summit Therapeutics trades 2,214 contracts. The company has the following event: Clinical Trial Collaboration to Evaluate Ivonescimab in Combination with GSK's B7-H3 Antibody Drug Conjugate on Jun 15, 2026.
Summit Therapeutics trades 11,307 contracts. The company has the following event: Clinical Trial Collaboration to Evaluate Ivonescimab in Combination with GSK's B7-H3 Antibody Drug Conjugate on Jun 15, 2026.
Summit Therapeutics trades 5,600 contracts. The company has the following event: Clinical Trial Collaboration to Evaluate Ivonescimab in Combination with GSK's B7-H3 Antibody Drug Conjugate on Jun 15, 2026.